title: ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
abstract: Improving the antitumor potency of current oncolytic adenoviruses represents one of the major challenges in development of these viruses for clinical use. We have generated an oncolytic adenovirus carrying the safety-enhancing E1AΔ24 deletion, the potency-enhancing T1 mutation, and the infectivity-enhancing fiber RGD modification. The results of in vitro cytotoxicity assays on 15 human cancer cell lines derived from different tumor types demonstrated that ORCA-010 is more potent than Ad5-Δ24RGD or ONYX-015. As ORCA-010 will initially be developed for the treatment of prostate cancer, selectivity experiments were performed using primary human prostate cells. ORCA-010 killed cancer cells more effectively than these primary human cells. In both primary prostate fibroblasts and epithelial cells, ORCA-010 was as safe as Ad5-Δ24RGD. Evaluation of ORCA-010 in in vivo xenograft tumor models in nude mice showed that ORCA-010 significantly inhibited growth of prostate, lung, and ovarian tumors and conferred prolonged survival of tumor-bearing animals. Furthermore, we observed a substantial increase in infectious viral particles in tumors injected with ORCA-010. The number of infectious viral particles increased after treatment and infectious particles remained present up to at least 4 weeks posttreatment. Intratumoral virus replication was associated with substantial necrosis and fibrosis. In conclusion, ORCA-010 is more potent than earlier generation oncolytic adenoviruses, without demonstrating increased toxicity. ORCA-010 exerted strong in vivo antitumor activity and is therefore a suitable candidate for clinical evaluation.
authors.affiliation: 1 ORCA Therapeutics B.V. , 1081 HZ Amsterdam, The Netherlands .
authors.forename: Wenliang
authors.initials: W
authors.lastname: Dong
authors.forename: Jan-Willem H
authors.initials: JW
authors.lastname: van Ginkel
authors.forename: Kam Y
authors.initials: KY
authors.lastname: Au
authors.forename: Ramon
authors.initials: R
authors.lastname: Alemany
authors.forename: Janneke J M
authors.initials: JJ
authors.lastname: Meulenberg
authors.forename: Victor W
authors.initials: VW
authors.lastname: van Beusechem
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D003588:Cytopathogenic Effect, Viral; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D023061:Gene Order; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics*; D047368:Tumor Burden; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
references.citation: Nat Protoc. 2007;2(1):31-4
references.pmid: 17401334
references.citation: Mol Ther. 2013 Oct;21(10):1814-8
references.pmid: 24081122
references.citation: Cancer Gene Ther. 2009 Jan;16(1):33-43
references.pmid: 18670453
references.citation: Oncogene. 2000 Jan 6;19(1):2-12
references.pmid: 10644974
references.citation: Virology. 1968 Sep;36(1):115-25
references.pmid: 5669982
references.citation: Int J Cancer. 2012 Apr 15;130(8):1937-47
references.pmid: 21630267
references.citation: Science. 1996 Oct 18;274(5286):373-6
references.pmid: 8832876
references.citation: Nat Med. 2000 Oct;6(10):1134-9
references.pmid: 11017145
references.citation: J Virol. 1998 Dec;72(12):9706-13
references.pmid: 9811704
references.citation: Cancer Res. 2006 Jan 15;66(2):989-98
references.pmid: 16424034
references.citation: Clin Cancer Res. 2001 Jan;7(1):120-6
references.pmid: 11205899
references.citation: Cancer Res. 2008 Nov 1;68(21):8928-37
references.pmid: 18974137
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5277-87
references.pmid: 20978148
references.citation: Cancer Res. 1999 Jan 15;59(2):410-3
references.pmid: 9927055
references.citation: Cancer Res. 2002 Nov 1;62(21):6165-71
references.pmid: 12414643
references.citation: Oncogene. 2006 Mar 9;25(10):1509-20
references.pmid: 16247442
references.citation: Nat Biotechnol. 2012 Jul 10;30(7):658-70
references.pmid: 22781695
references.citation: J Clin Invest. 1999 Feb;103(4):579-87
references.pmid: 10021467
references.citation: Mol Aspects Med. 2007 Feb;28(1):42-58
references.pmid: 17300834
references.citation: Hum Gene Ther. 1996 Jan 20;7(2):215-22
references.pmid: 8788172